NDRA PE Ratio & Valuation, Is NDRA Overvalued

Historical Valuation

ENDRA Life Sciences Inc (NDRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.09. The fair price of ENDRA Life Sciences Inc (NDRA) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：3.76

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is ENDRA Life Sciences Inc (NDRA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

ENDRA Life Sciences Inc (NDRA) has a current Price-to-Book (P/B) ratio of 19.70. Compared to its 3-year average P/B ratio of 3.39, the current P/B ratio is approximately 480.76% higher. Relative to its 5-year average P/B ratio of 3.17, the current P/B ratio is about 521.02% higher. ENDRA Life Sciences Inc (NDRA) has a Forward Free Cash Flow (FCF) yield of approximately -101.99%. Compared to its 3-year average FCF yield of -187.62%, the current FCF yield is approximately -45.64% lower. Relative to its 5-year average FCF yield of -131.28%, the current FCF yield is about -22.31% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NDRA competitors is 0.13, providing a benchmark for relative valuation. ENDRA Life Sciences Inc Corp (NDRA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NDRA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NDRA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NDRA currently overvalued or undervalued?

What is ENDRA Life Sciences Inc (NDRA) fair value?

NDRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of ENDRA Life Sciences Inc (NDRA) is between to according to relative valuation method.

How does NDRA's valuation metrics compare to the industry average?

The average P/S ratio for NDRA's competitors is 0.13, providing a benchmark for relative valuation. ENDRA Life Sciences Inc Corp (NDRA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for ENDRA Life Sciences Inc (NDRA) as of Mar 25 2026?

As of Mar 25 2026, ENDRA Life Sciences Inc (NDRA) has a P/B ratio of 19.70. This indicates that the market values NDRA at 19.70 times its book value.

What is the current FCF Yield for ENDRA Life Sciences Inc (NDRA) as of Mar 25 2026?

As of Mar 25 2026, ENDRA Life Sciences Inc (NDRA) has a FCF Yield of -101.99%. This means that for every dollar of ENDRA Life Sciences Inc's market capitalization, the company generates -101.99 cents in free cash flow.

What is the current Forward P/E ratio for ENDRA Life Sciences Inc (NDRA) as of Mar 25 2026?

As of Mar 25 2026, ENDRA Life Sciences Inc (NDRA) has a Forward P/E ratio of -0.91. This means the market is willing to pay $-0.91 for every dollar of ENDRA Life Sciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for ENDRA Life Sciences Inc (NDRA) as of Mar 25 2026?

As of Mar 25 2026, ENDRA Life Sciences Inc (NDRA) has a Forward P/S ratio of 0.00. This means the market is valuing NDRA at $0.00 for every dollar of expected revenue over the next 12 months.

NDRA Valuation